Citius Oncology (NASDAQ:CTOR) Trading Up 11.5% – What’s Next?

Citius Oncology, Inc. (NASDAQ:CTOR)’s stock price traded up 11.5% during mid-day trading on Monday . The stock traded as high as $0.70 and last traded at $0.6913. 33,490 shares were traded during trading, a decline of 45% from the average daily volume of 61,252 shares. The stock had previously closed at $0.62.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Citius Oncology in a research note on Tuesday, June 16th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $6.00.

Citius Oncology Stock Performance

The company has a debt-to-equity ratio of 0.11, a current ratio of 0.50 and a quick ratio of 0.12. The stock has a fifty day simple moving average of $0.81 and a two-hundred day simple moving average of $0.92. The firm has a market capitalization of $65.49 million, a P/E ratio of -1.50 and a beta of 3.41.

Citius Oncology (NASDAQ:CTOR) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.26). The business had revenue of $1.67 million during the quarter, compared to analysts’ expectations of $7.00 million.

Institutional Investors Weigh In On Citius Oncology

A number of large investors have recently bought and sold shares of CTOR. Armistice Capital LLC acquired a new position in shares of Citius Oncology during the third quarter valued at about $15,582,000. Bank of America Corp DE grew its stake in shares of Citius Oncology by 1,792,030.8% in the 1st quarter. Bank of America Corp DE now owns 3,835,160 shares of the company’s stock valued at $2,374,000 after buying an additional 3,834,946 shares during the period. Geode Capital Management LLC grew its stake in shares of Citius Oncology by 31.6% in the 4th quarter. Geode Capital Management LLC now owns 220,047 shares of the company’s stock valued at $220,000 after buying an additional 52,875 shares during the period. Jane Street Group LLC bought a new stake in Citius Oncology in the 2nd quarter valued at about $465,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in Citius Oncology in the 4th quarter valued at about $104,000. 70.52% of the stock is currently owned by institutional investors and hedge funds.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.